Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients - Takeaways - MDSpire

Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients

  • By

  • Carmine Valenza

  • Yue Zheng

  • Monica Milano

  • Pier Paolo Maria Berton Giachetti

  • Dario Trapani

  • Elisa Giordano

  • Lorenzo Guidi

  • Laura Boldrini

  • Grazia Castellano

  • Jalissa Katrini

  • Bianca Malagutti

  • Gabriele Antonarelli

  • Julian D. Etessami

  • Nadia Bianco

  • Fabio Conforti

  • Gregory J. Kirkner

  • Claudia Sangalli

  • Kate E. Dibble

  • Nicola Fusco

  • Marco Colleoni

  • Meredith M. Regan

  • Elisabetta Munzone

  • Giuseppe Curigliano

  • Ann H. Partridge

  • May 4, 2026

  • 0 min

Share

  • 1

    Breast cancer is the leading cause of cancer-related morbidity and mortality among women aged 40 years or younger.

  • 2

    Younger patients often present with more advanced disease and have a poorer prognosis, especially in hormone receptor-positive cases.

  • 3

    Extended endocrine therapy (EET) after initial treatment is linked to lower rates of invasive and distant recurrence in premenopausal women.

  • 4

    Patterns of recurrence differ by breast cancer subtype, with luminal B-like tumors showing higher early recurrence risk compared to luminal A-like tumors.

  • 5

    The study aims to evaluate the benefits of EET in premenopausal women with node-positive, hormone receptor-positive early breast cancer.

Original Source(s)

Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients

  • by Carmine Valenza, Yue Zheng, Monica Milano, Pier Paolo Maria Berton Giachetti, Dario Trapani, Elisa Giordano, Lorenzo Guidi, Laura Boldrini, Grazia Castellano, Jalissa Katrini, Bianca Malagutti, Gabriele Antonarelli, Julian D. Etessami, Nadia Bianco, Fabio Conforti, Gregory J. Kirkner, Claudia Sangalli, Kate E. Dibble, Nicola Fusco, Marco Colleoni, Meredith M. Regan, Elisabetta Munzone, Giuseppe Curigliano, Ann H. Partridge

  • May 4, 2026

Related Content

Clinical implications of 10-formyltetrahydrofolate dehydrogenase expression in hormone receptor-positive breast cancer

Spatial organization of the tumor immune microenvironment in LAR+ triple-negative breast cancer

Dana-Farber Research News 05.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from April 16 - 30.

  • by

  • May 15, 2026

  • 21 min